Non-Hodgkin lymphoma statistics

Cases

New cases of non-Hodgkin lymphoma, 2015, UK

Deaths

Deaths from non-Hodgkin lymphoma, 2016, UK

Survival

Survive non-Hodgkin lymphoma for 10 or more years, 2010-11, England and Wales

Preventable cases

Non-Hodgkin lymphoma cases are preventable, UK, 2015

 

  • There are around 13,700 new non-Hodgkin lymphoma cases in the UK every year, that's 38 every day (2013-2015).
  • Non-Hodgkin lymphoma is the 6th most common cancer in the UK, accounting for 4% of all new cancer cases (2015).
  • In males in the UK, non-Hodgkin lymphoma is the 7th most common cancer, with around 7,500 new cases in 2015.
  • In females in the UK, non-Hodgkin lymphoma is the 7th most common cancer, with around 6,200 new cases in 2015.
  • Incidence rates for non-Hodgkin lymphoma in the UK are highest in people aged 80 to 84 (2013-2015).
  • Since the early 1990s, non-Hodgkin lymphoma incidence rates have increased by almost two-fifths (39%) in the UK. Rates in males have increased by more than a third (36%), and rates in females have increased by two-fifths (40%).
  • Over the last decade, non-Hodgkin lymphoma incidence rates have increased by almost a sixth (16%) in the UK. Rates in males have increased by a sixth (17%), and rates in females have increased by around a seventh (15%).
  • Most non-Hodgkin lymphoma cases are diagnosed at a late stage.
  • Incidence rates for non-Hodgkin lymphoma are projected to fall by 2% in the UK between 2014 and 2035, to 26 cases per 100,000 people by 2035.
  • Non-Hodgkin lymphoma in England is more common in females living in the most deprived areas. There is no association for males.
  • NHL is as common in White, Asian and Black people.
  • An estimated 76,800 people who had previously been diagnosed with non-Hodgkin lymphoma were alive in the UK at the end of 2010.
  • In Europe, around 93,500 new cases of NHL were estimated to have been diagnosed in 2012. The UK incidence rate is ninth highest in Europe for males and eighth highest for females.
  • Worldwide, nearly 386,000 new cases of NHL (all subtypes combined) were estimated to have been diagnosed in 2012, with incidence rates varying across the world.

See more in-depth NHL incidence statistics

  • There are around 4,900 non-Hodgkin lymphoma deaths in the UK every year, that's 13 every day (2014-2016).
  • Non-Hodgkin lymphoma is the 11th most common cause of cancer death in the UK, accounting for 3% of all cancer deaths (2016).
  • In males in the UK, non-Hodgkin lymphoma is the 13th most common cause of cancer death, with around 2,700 deaths in 2016.
  • In females in the UK, non-Hodgkin lymphoma is the 10th most common cause of cancer death, with around 2,200 deaths in 2016.
  • Mortality rates for non-Hodgkin lymphoma in the UK are highest in people aged 85 to 89 (2014-2016).
  • Since the early 1970s, non-Hodgkin lymphoma mortality rates have increased by more than four-fifths (82%) in the UK. Rates in males have increased by almost nine-tenths (86%), and rates in females have increased by three-quarters (75%).
  • Over the last decade, non-Hodgkin lymphoma mortality rates have decreased by around a twentieth (6%) in the UK. Rates in males have remained stable, and rates in females have decreased by around a tenth (9%).
  • Mortality rates for non-Hodgkin lymphoma are projected to fall by 20% in the UK between 2014 and 2035, to 8 deaths per 100,000 people by 2035.
  • Non-Hodgkin lymphoma deaths in England are more common in females living in the most deprived areas. There is no association for males.
  • In Europe, around 37,900 people were estimated to have died from NHL in 2012. The UK mortality rate is sixth highest in Europe for males and eighth highest for females.
  • Worldwide, more than 199,000 people were estimated to have died from NHL (all subtypes combined) in 2012, with mortality rates varying across the world.

See more in-depth NHL mortality statistics

  • Almost two-thirds (63%) of people diagnosed with Non-Hodgkin lymphoma in England and Wales survive their disease for ten years or more (2010-11).
  • Around 7 in 10 (69%) of people diagnosed with Non-Hodgkin lymphoma cancer in England and Wales survive their disease for five years or more (2010-11).
  • 8 in 10 (80%) of people/men/women diagnosed with Non-Hodgkin lymphoma cancer in England and Wales survive their disease for one year or more (2010-11).
  • Non-Hodgkin lymphoma survival is similar in men than women.
  • Non-Hodgkin lymphoma survival in England is highest for people diagnosed aged under 40 (2009-2013).
  • Almost 9 in 10 people in England diagnosed with Non-Hodgkin lymphoma aged 15-39 survive their disease for five years or more, compared with more than 4 in 10 people diagnosed aged 80 and over (2009-2013).
  • Non-Hodgkin lymphoma survival is improving and has tripled in the last 40 years in the UK.
  • In the 1970s, more than a fifth of people diagnosed with Non-Hodgkin lymphoma cancer survived their disease beyond ten years, now it's almost two-thirds.
  • When diagnosed at its earliest stage, 7 in 10 people with Non-Hodgkin lymphoma will survive their disease for five years or more, compared with less than 6 in 10 of people when diagnosed at the latest stage.
  • Five-year relative survival for non-Hodgkin lymphoma in men is below the European average in England and Wales but similar to the European average in Scotland and Northern Ireland.
  • Five-year relative survival for non-Hodgkin lymphoma in women is below the European average in England but similar to the European average in Wales, Scotland and Northern Ireland.

See more in-depth NHL survival statistics

  • A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
  • 1 in 39 UK males and 1 in 51 UK females will be diagnosed with non-Hodgkin lymphoma in their lifetime.
  • 3% of non-Hodgkin lymphoma cases in the UK are preventable.

See more in-depth NHL risk statistics

  • 'GP referral' is the most common route to diagnosing non-Hodgkin lymphoma (NHL).
  • 'Two week wait' is the route with the highest proportion of cases diagnosed at an early stage, for NHL.
  • ‘Two-week wait’ and ’31-day wait’ standards are met by all countries, and ‘62-day wait’ is not met by any country for haematological cancers.

See more in-depth NHL diagnosis and treatment statistics

Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.

The latest statistics available for non-Hodgkin lymphoma (NHL) are; incidence 2015, mortality 2016 and survival 2010-2011 (all ages combined) and 2009-2013 (by age).

The ICD codes Open a glossary item for NHL incidence and mortality are ICD-10 C82-C86.

The ICD codes for NHL survival are ICD-10 C82-C85.

European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.

NHL statistics by subtype are provided for the Haematological Malignancy Research Network (HMRN) region. HMRN covers a population of 3.6 million and is set within the former adjacent UK Cancer Networks of Yorkshire and the Humber & Yorkshire Coast England. While HMRN may not be fully representative of the country as a whole due to variation in local healthcare provision standards and policies, the population does have a similar socio-demographic profile to the UK.

Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages, stages Open a glossary item and co-morbidities . The survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Meta-analyses Open a glossary item and systematic reviews Open a glossary item are cited where available, as they provide the best overview of all available research and most take study quality into account. Individual case-control and cohort Open a glossary item studies are reported where such aggregated data are lacking.

Overall, the evidence on NHL risk factors is limited, mainly because of the relative rarity and diversity of this cancer type; most research examines immune system-related factors.

Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2012-2013. Staging proportions only include patients with a known stage (cases with an unknown stage at diagnosis are not included in the denominator).

Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. NHL is part of the group 'Haematological cancers' for cancer waiting times data. Codes vary per country but broadly include: Hodgkin lymphoma, follicular and non-follicular lymphoma, mature T/NK-caell lymphoma, other and unspecified types of NHL, other and unspecified types of T/NK-cell lymphoma, malignant immunoproliferative diseases, myeloma, lymphoid, myeloid and monocytic leukaemia, some other leukaemia of specific or unspecified cell type, and other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue.

Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.

Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 3.7 out of 5 based on 23 votes
Thank you!
We've recently made some changes to the site, tell us what you think